Santarus to Present Phase Rifamycin SV MMX III Data

Santarus SNTS today announced that new data from its Phase III clinical study with the investigational drug rifamycin SV MMX® in patients with travelers' diarrhea will be featured in a poster presentation at IDWeek™ in San Francisco at the Moscone Center (Poster Hall C) from 12:30 p.m. to 2:00 p.m. Pacific Time on Saturday, October 5, 2013. The poster (#1306) is titled, Randomized, Double-Blind, Placebo-Controlled Study of Rifamycin SV MMX in the Treatment of Travelers' Diarrhea. IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). “The data from this clinical study indicate that rifamycin SV MMX significantly shortened the duration of travelers' diarrhea and was well tolerated, with adverse events similar to that of placebo in the study. In addition, rifamycin SV MMX demonstrated broad activity, and of interest was the possible activity against invasive pathogens,” said Herbert L. DuPont, M.D., principal investigator and lead author of the poster. Dr. DuPont is Director of the Center for Infectious Diseases and Professor of Infectious Diseases at the University of Texas – Houston School of Public Health, Chief of Internal Medicine at St. Luke's Hospital and Vice Chairman, Department of Medicine and Clinical Professor at the Baylor College of Medicine. The company has previously announced that the Phase III study met the primary endpoint of reducing the time to last unformed stool (TLUS) in the intent-to-treat (ITT) population. A summary of the efficacy and safety data from the study is presented below.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsEvents
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!